Octreoscan (Indium In-111 Pentetreotide)

Octreoscan is used in diagnostic imaging of somatostatin receptor‑positive neuroendocrine tumors.

• Neuroendocrine tumors (NETs): enables whole‑body scintigraphy to locate primary and metastatic lesions.
• Carcinoid tumors: assists in staging and treatment planning by visualising receptor‑expressing disease.
• Medullary thyroid carcinoma: detects somatostatin receptor expression for disease assessment.
• Pheochromocytoma and paraganglioma: images receptor‑positive lesions to guide management.

• Indium‑111 pentetreotide is a somatostatin analog labeled with the gamma‑emitting radionuclide indium‑111. After intravenous injection it binds with high affinity to somatostatin receptor subtypes, especially sst2, on tumor cells. The bound radionuclide emits photons that are captured by gamma cameras, producing high‑resolution images of receptor‑expressing tissues for diagnostic evaluation.

Common Side Effects

• Nausea: mild, transient after injection.
• Flushing: brief sensation of warmth or redness.
• Injection site pain: mild discomfort at the venipuncture site.
• Headache: occasional, self‑limiting.
• Transient hypotension: short‑lasting drop in blood pressure.
• Mild abdominal discomfort: brief and usually resolves.

Serious or Rare Side Effects

• Severe allergic reaction or anaphylaxis: requires immediate medical attention.
• Significant hypotension: may need supportive measures.
• Radiation‑induced marrow suppression: rare, monitor blood counts.
• Renal toxicity: possible in patients with pre‑existing kidney impairment.
• Severe bronchospasm: especially in patients with reactive airway disease.
• Acute radiation syndrome: extremely rare, associated with dosing errors.

Octreoscan should be used with careful consideration of patient‑specific factors and handling requirements.

• Pregnancy: avoid unless essential; radiation may harm the fetus.
• Breastfeeding: discontinue breastfeeding for the period recommended by the prescribing physician.
• Renal function: assess before administration as the agent is cleared renally.
• Known hypersensitivity: screen for allergy to pentetreotide or indium compounds.
• Concurrent radiopharmaceuticals: avoid administration of other diagnostic radionuclides within 24 hours.
• Store at ambient temperature: keep in original shielding container, protect from light and moisture.

Octreoscan may interact with other agents that affect receptor binding or radiation exposure.

Major Interactions (Avoid)

• Other radiopharmaceuticals (e.g., I‑131) within 24 h: may cause imaging interference.
• High‑dose somatostatin analog therapy (e.g., octreotide): competes for receptor sites and reduces uptake.
• Cytotoxic chemotherapy causing severe marrow suppression: may increase radiation toxicity.

Moderate Interactions (Monitor Closely)

• Diuretics: may alter renal clearance of the agent.
• ACE inhibitors: can potentiate hypotensive effects.
• Contrast agents used in CT: may affect interpretation of scintigraphic images.
• Antihistamines: may mask mild allergic reactions.
• Beta‑blockers: could influence cardiovascular response to the injection.